Ed Peng1, John J O'Sullivan2, Massimo Griselli1, Chandrika Roysam3, David Crossland2, Milind Chaudhari2, Neil Wrightson4, Tanveer Butt4, Gareth Parry4, Guy A MacGowan4, Stephan Schueler4, Asif Hasan5. 1. Children's Heart Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; Cardiopulmonary Transplant Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom. 2. Children's Heart Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom. 3. Cardiothoracic Anaesthesia, Freeman Hospital, Newcastle Upon Tyne, United Kingdom. 4. Cardiopulmonary Transplant Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom. 5. Children's Heart Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom; Cardiopulmonary Transplant Unit, Freeman Hospital, Newcastle Upon Tyne, United Kingdom. Electronic address: asif.hasan@nuth.nhs.uk.
Abstract
BACKGROUND: The systemic morphologic right ventricle (RV) in congenitally corrected transposition of the great arteries or after atrial switch for transposition of the great arteries is associated with late ventricular failure. Although the role of the left ventricular assist device (LVAD) in supporting the failing LV is established, the indications and outcomes of using LVAD in a systemic RV remain unclear. We assessed the role of a third-generation LVAD for systemic RV support. METHODS: Seven patients (mean age, 36 years) received the HeartWare (HeartWare International Inc, Framingham, MA) VAD for systemic RV failure (congenitally corrected transposition of the great arteries in 1 and after atrial switch in 6). Four patients (57%) had severe subpulmonic LV failure, and aggressive perioperative diuresis with or without hemofiltration was used to offload the subpulmonic LV. The indications of VAD were (1) bridge to transplant in 3 and (2) bridge to decision for a high transpulmonary gradient in 4. Transplantation outcome was compared with systemic RV failure without VAD bridge in 19 patients (years 1989 to 2013). RESULTS: Systemic RV support alone was achieved in all patients, with no early deaths (≤30 days). Overall, 6 (86%) returned home, 3 (44%) received a transplant, 2 (28%) died of noncardiac causes, and 2 (28%) continue on VAD support (median support, 232 days). Repeat catheterization (n = 4) showed an improved median transpulmonary gradient in 3 patients (median 18.5 mm Hg pre-VAD vs 8.0 mm Hg post-VAD). Two bridge-to-decision patients received transplants at 640 and 685 days. The stroke rate on VAD support was 43% (2 thromboembolic and 1 hemorrhagic; 3 with satisfactory recovery). De novo aortic regurgitation was 29% (n = 2; 1 valve replacement). All patients (n = 3) survived transplantation (vs 10.5% early mortality without VAD bridge; p = 1.00) and were well at follow-up (range, 53 to 700 days). CONCLUSIONS: The third-generation VAD provides durable support for systemic RV failure as a bridge to transplant and as a strategy to reduce pulmonary vascular resistance. Although concomitant subpulmonic LV failure is common, systemic RV support alone was achieved in all patients.
BACKGROUND: The systemic morphologic right ventricle (RV) in congenitally corrected transposition of the great arteries or after atrial switch for transposition of the great arteries is associated with late ventricular failure. Although the role of the left ventricular assist device (LVAD) in supporting the failing LV is established, the indications and outcomes of using LVAD in a systemic RV remain unclear. We assessed the role of a third-generation LVAD for systemic RV support. METHODS: Seven patients (mean age, 36 years) received the HeartWare (HeartWare International Inc, Framingham, MA) VAD for systemic RV failure (congenitally corrected transposition of the great arteries in 1 and after atrial switch in 6). Four patients (57%) had severe subpulmonic LV failure, and aggressive perioperative diuresis with or without hemofiltration was used to offload the subpulmonic LV. The indications of VAD were (1) bridge to transplant in 3 and (2) bridge to decision for a high transpulmonary gradient in 4. Transplantation outcome was compared with systemic RV failure without VAD bridge in 19 patients (years 1989 to 2013). RESULTS: Systemic RV support alone was achieved in all patients, with no early deaths (≤30 days). Overall, 6 (86%) returned home, 3 (44%) received a transplant, 2 (28%) died of noncardiac causes, and 2 (28%) continue on VAD support (median support, 232 days). Repeat catheterization (n = 4) showed an improved median transpulmonary gradient in 3 patients (median 18.5 mm Hg pre-VAD vs 8.0 mm Hg post-VAD). Two bridge-to-decision patients received transplants at 640 and 685 days. The stroke rate on VAD support was 43% (2 thromboembolic and 1 hemorrhagic; 3 with satisfactory recovery). De novo aortic regurgitation was 29% (n = 2; 1 valve replacement). All patients (n = 3) survived transplantation (vs 10.5% early mortality without VAD bridge; p = 1.00) and were well at follow-up (range, 53 to 700 days). CONCLUSIONS: The third-generation VAD provides durable support for systemic RV failure as a bridge to transplant and as a strategy to reduce pulmonary vascular resistance. Although concomitant subpulmonic LV failure is common, systemic RV support alone was achieved in all patients.
Authors: Rhoia Neidenbach; Koichiro Niwa; Oeztekin Oto; Erwin Oechslin; Jamil Aboulhosn; David Celermajer; Joerg Schelling; Lars Pieper; Linda Sanftenberg; Renate Oberhoffer; Fokko de Haan; Michael Weyand; Stephan Achenbach; Christian Schlensak; Dirk Lossnitzer; Nicole Nagdyman; Yskert von Kodolitsch; Hans-Carlo Kallfelz; David Pittrow; Ulrike M M Bauer; Peter Ewert; Thomas Meinertz; Harald Kaemmerer Journal: Cardiovasc Diagn Ther Date: 2018-12
Authors: Jill M Steiner; Eric V Krieger; Karen K Stout; April Stempien-Otero; Claudius Mahr; Nahush A Mokadam; Joshua L Hermsen Journal: Int J Cardiol Date: 2017-08-02 Impact factor: 4.164
Authors: Marketa Hegarova; Jaroslav Brotanek; Milos Kubanek; Radka Kockova; Janka Franekova; Vera Lanska; Ivan Netuka; Vojtech Melenovsky; Ivan Malek; Josef Kautzner Journal: Croat Med J Date: 2016-08-31 Impact factor: 1.351
Authors: David Steven Crossland; Katrijn Jansen; Gareth Parry; Andrew Harper; Gianluigi Perri; Alison Davidson; Fabrizio De Rita; Antony Hermuzi; Mohamed Nassar; Neil Seller; Guy A MacGowan; Asif Hasan; John J O'Sullivan; Louise Coats Journal: Heart Date: 2019-07-05 Impact factor: 5.994